MediciNova, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MNOV research report →
About the company
MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions.
- CEO
- Yuichi Iwaki
- IPO
- 2006
- Employees
- 13
- HQ
- La Jolla, CA, US
Price Chart
- Market Cap
- $70.39M
- P/E
- -6.11
- P/S
- 117.97
- P/B
- 1.79
- EV/EBITDA
- -3.69
- Div Yield
- 0.00%
- Gross Margin
- 15.20%
- Op Margin
- -2164.84%
- Net Margin
- -1964.35%
- ROE
- -27.29%
- ROIC
- -32.47%
- Revenue
- $409.66K · 0.00%
- Net Income
- $-11,997,957 · -8.58%
- EPS
- $-0.24 · -4.35%
- Op Income
- $-13,283,000
- FCF YoY
- 7.83%
- 52W High
- $1.96
- 52W Low
- $1.17
- 50D MA
- $1.36
- 200D MA
- $1.41
- Beta
- 0.62
- Avg Volume
- 40.98K
Get TickerSpark's AI analysis on MNOV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 23, 26 | Nagao Hideki | other | 44,500 |
| Jun 23, 26 | Lemerond Nicole | other | 44,500 |
| Jun 23, 26 | BEAVER CAROLYN | other | 44,500 |
| Jan 16, 26 | Matsuda Kazuko | other | 350,000 |
| Jan 16, 26 | IWAKI YUICHI | other | 450,000 |
| Jun 17, 25 | Nagao Hideki | other | 20,000 |
| Jun 17, 25 | Lemerond Nicole | other | 20,000 |
| Jun 17, 25 | BEAVER CAROLYN | other | 20,000 |
| Feb 12, 25 | Nagao Hideki | other | 24,500 |
| Feb 12, 25 | Matsuda Kazuko | other | 100,000 |
Our MNOV coverage
Recent articles, reports, and earnings notes.
No research on MNOV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MNOV report →Similar companies
Peers in the same neighborhood.